Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients

William J. Kowalczyk, Jeremiah W. Bertz, Landhing M. Moran, Karran A. Phillips, Udi E. Ghitza, David H. Epstein, Kenzie L. Preston

Research output: Contribution to journalArticle

Abstract

Objective: In a clinical trial examining daily clonidine as an adjunct to buprenorphine treatment for opioid dependence, we found that clonidine increased opioid abstinence and decoupled stress from craving. From a personalized-medicine perspective, the next step is to identify people for whom clonidine would be beneficial. To that end, using data from the same clinical trial, we examined the associations of daily-life activities with treatment success. Methods: Outpatients (N=118) received clonidine (0.3mg/d) or placebo during 18 weeks of buprenorphine treatment. Participants carried a smartphone that randomly prompted them 4 times per day to report their moods and activities. Using generalized linear mixed models, we assessed the likelihoods of different types of daily activity as a function of clonidine versus placebo, days of longest continuous opioid abstinence, and their interaction. Results: Participants in the buprenorphine-only (buprenorphine plus placebo) control group who engaged in more responsibilities (work and child/elder care) had longer streaks of abstinence, whereas those who engaged in more unstructured-time activities had shorter streaks of abstinence. Conversely, for participants in the buprenorphine-plus-clonidine group, longer streaks of abstinence were associated with higher frequencies of activities associated with "unstructured" time. Conclusions: The study replicates findings that engaging in responsibilities is related to positive treatment outcomes in standard opioid agonist therapy. The pattern of results also suggests that clonidine helped participants engage in unstructured-time activities with less risk of craving or use than they might otherwise have had.

Original languageEnglish (US)
Pages (from-to)454-460
Number of pages7
JournalJournal of Addiction Medicine
Volume11
Issue number6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Buprenorphine
Clonidine
Outpatients
Opioid Analgesics
Placebos
Clinical Trials
Precision Medicine
Therapeutics
Child Care
Linear Models
Control Groups

Keywords

  • buprenorphine treatment
  • clonidine
  • ecological momentary assessment
  • opioid treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Kowalczyk, W. J., Bertz, J. W., Moran, L. M., Phillips, K. A., Ghitza, U. E., Epstein, D. H., & Preston, K. L. (2017). Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients. Journal of Addiction Medicine, 11(6), 454-460. https://doi.org/10.1097/ADM.0000000000000345

Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients. / Kowalczyk, William J.; Bertz, Jeremiah W.; Moran, Landhing M.; Phillips, Karran A.; Ghitza, Udi E.; Epstein, David H.; Preston, Kenzie L.

In: Journal of Addiction Medicine, Vol. 11, No. 6, 01.01.2017, p. 454-460.

Research output: Contribution to journalArticle

Kowalczyk, WJ, Bertz, JW, Moran, LM, Phillips, KA, Ghitza, UE, Epstein, DH & Preston, KL 2017, 'Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients', Journal of Addiction Medicine, vol. 11, no. 6, pp. 454-460. https://doi.org/10.1097/ADM.0000000000000345
Kowalczyk, William J. ; Bertz, Jeremiah W. ; Moran, Landhing M. ; Phillips, Karran A. ; Ghitza, Udi E. ; Epstein, David H. ; Preston, Kenzie L. / Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients. In: Journal of Addiction Medicine. 2017 ; Vol. 11, No. 6. pp. 454-460.
@article{cdc6a7aa1ebf4a86a415225f74c645a2,
title = "Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients",
abstract = "Objective: In a clinical trial examining daily clonidine as an adjunct to buprenorphine treatment for opioid dependence, we found that clonidine increased opioid abstinence and decoupled stress from craving. From a personalized-medicine perspective, the next step is to identify people for whom clonidine would be beneficial. To that end, using data from the same clinical trial, we examined the associations of daily-life activities with treatment success. Methods: Outpatients (N=118) received clonidine (0.3mg/d) or placebo during 18 weeks of buprenorphine treatment. Participants carried a smartphone that randomly prompted them 4 times per day to report their moods and activities. Using generalized linear mixed models, we assessed the likelihoods of different types of daily activity as a function of clonidine versus placebo, days of longest continuous opioid abstinence, and their interaction. Results: Participants in the buprenorphine-only (buprenorphine plus placebo) control group who engaged in more responsibilities (work and child/elder care) had longer streaks of abstinence, whereas those who engaged in more unstructured-time activities had shorter streaks of abstinence. Conversely, for participants in the buprenorphine-plus-clonidine group, longer streaks of abstinence were associated with higher frequencies of activities associated with {"}unstructured{"} time. Conclusions: The study replicates findings that engaging in responsibilities is related to positive treatment outcomes in standard opioid agonist therapy. The pattern of results also suggests that clonidine helped participants engage in unstructured-time activities with less risk of craving or use than they might otherwise have had.",
keywords = "buprenorphine treatment, clonidine, ecological momentary assessment, opioid treatment",
author = "Kowalczyk, {William J.} and Bertz, {Jeremiah W.} and Moran, {Landhing M.} and Phillips, {Karran A.} and Ghitza, {Udi E.} and Epstein, {David H.} and Preston, {Kenzie L.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/ADM.0000000000000345",
language = "English (US)",
volume = "11",
pages = "454--460",
journal = "Journal of Addiction Medicine",
issn = "1932-0620",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients

AU - Kowalczyk, William J.

AU - Bertz, Jeremiah W.

AU - Moran, Landhing M.

AU - Phillips, Karran A.

AU - Ghitza, Udi E.

AU - Epstein, David H.

AU - Preston, Kenzie L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: In a clinical trial examining daily clonidine as an adjunct to buprenorphine treatment for opioid dependence, we found that clonidine increased opioid abstinence and decoupled stress from craving. From a personalized-medicine perspective, the next step is to identify people for whom clonidine would be beneficial. To that end, using data from the same clinical trial, we examined the associations of daily-life activities with treatment success. Methods: Outpatients (N=118) received clonidine (0.3mg/d) or placebo during 18 weeks of buprenorphine treatment. Participants carried a smartphone that randomly prompted them 4 times per day to report their moods and activities. Using generalized linear mixed models, we assessed the likelihoods of different types of daily activity as a function of clonidine versus placebo, days of longest continuous opioid abstinence, and their interaction. Results: Participants in the buprenorphine-only (buprenorphine plus placebo) control group who engaged in more responsibilities (work and child/elder care) had longer streaks of abstinence, whereas those who engaged in more unstructured-time activities had shorter streaks of abstinence. Conversely, for participants in the buprenorphine-plus-clonidine group, longer streaks of abstinence were associated with higher frequencies of activities associated with "unstructured" time. Conclusions: The study replicates findings that engaging in responsibilities is related to positive treatment outcomes in standard opioid agonist therapy. The pattern of results also suggests that clonidine helped participants engage in unstructured-time activities with less risk of craving or use than they might otherwise have had.

AB - Objective: In a clinical trial examining daily clonidine as an adjunct to buprenorphine treatment for opioid dependence, we found that clonidine increased opioid abstinence and decoupled stress from craving. From a personalized-medicine perspective, the next step is to identify people for whom clonidine would be beneficial. To that end, using data from the same clinical trial, we examined the associations of daily-life activities with treatment success. Methods: Outpatients (N=118) received clonidine (0.3mg/d) or placebo during 18 weeks of buprenorphine treatment. Participants carried a smartphone that randomly prompted them 4 times per day to report their moods and activities. Using generalized linear mixed models, we assessed the likelihoods of different types of daily activity as a function of clonidine versus placebo, days of longest continuous opioid abstinence, and their interaction. Results: Participants in the buprenorphine-only (buprenorphine plus placebo) control group who engaged in more responsibilities (work and child/elder care) had longer streaks of abstinence, whereas those who engaged in more unstructured-time activities had shorter streaks of abstinence. Conversely, for participants in the buprenorphine-plus-clonidine group, longer streaks of abstinence were associated with higher frequencies of activities associated with "unstructured" time. Conclusions: The study replicates findings that engaging in responsibilities is related to positive treatment outcomes in standard opioid agonist therapy. The pattern of results also suggests that clonidine helped participants engage in unstructured-time activities with less risk of craving or use than they might otherwise have had.

KW - buprenorphine treatment

KW - clonidine

KW - ecological momentary assessment

KW - opioid treatment

UR - http://www.scopus.com/inward/record.url?scp=85033802436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033802436&partnerID=8YFLogxK

U2 - 10.1097/ADM.0000000000000345

DO - 10.1097/ADM.0000000000000345

M3 - Article

C2 - 28759482

AN - SCOPUS:85033802436

VL - 11

SP - 454

EP - 460

JO - Journal of Addiction Medicine

JF - Journal of Addiction Medicine

SN - 1932-0620

IS - 6

ER -